In sorafenib-resistant HCC cells, Wang et al. could demonstrate that GTSZ1 was downregulated, and this observation was associated with NRF2 pathway activation and increased GPX4 levels [103]. The gene discussed is GPX4; the disease is hepatocellular carcinoma.